Wim Jongen
Président chez Netherlands Translational Research Center BV
Profil
Wim M.
F.
Jongen is currently the Chairman of Netherlands Translational Research Center BV, Director of Isobionics BV, and Director of Glycostem Therapeutics BV.
He is also a Partner at Westertoren Innovation Ventures BV since 2009.
Previously, he served as the Chief Executive Officer of Wageningen Business Generator BV and Glycostem Therapeutics BV, Chairman-Supervisory Board of Pepscan Therapeutics BV and Streaming Valley BV, and Director of Support Fund (Management) from 2010 to 2017.
He also worked as a Professor at Wageningen University.
He holds a doctorate degree from Wageningen University.
Postes actifs de Wim Jongen
| Sociétés | Poste | Début |
|---|---|---|
Westertoren Innovation Ventures BV
 Westertoren Innovation Ventures BV Investment ManagersFinance Westertoren Innovation Ventures BV (Westertoren Innovation Ventures) is a private equity and venture capital subsidiary of Biox Biosciences BV headquartered in 's-Hertogenbosch, Netherlands. The firm was founded in 2009. | Private Equity Investor | 01/01/2009 |
Netherlands Translational Research Center BV
 Netherlands Translational Research Center BV Medical/Nursing ServicesHealth Services Netherlands Translational Research Center BV develops small molecule drug leads and preclinical candidates for cancer, autoimmune and Parkinson diseases. Its product NFK GreenScreen plays an important role in immune modulation and neurodegenerative disease. The firm also offers Oncolines, OncolinesProfiler, SynergyFinder, ResidenceTimer and EntropySelect services. The company was founded by Guido J. R. Zaman and Rogier C. Buijsman in June 2011 and is headquartered in Oss, the Netherlands. | Président | - |
Isobionics BV
 Isobionics BV Chemicals: Major DiversifiedProcess Industries Isobionics BV operates as a holding company, which produces flavor and fragrance ingredients. The firm manufactures and supplies natural chemical substances such as Valencene, Nootkatone, and Beta-Elemene. The company was founded by Toine Janssen in 2008 and is headquartered in Geleen, the Netherlands. | Directeur/Membre du Conseil | - |
Glycostem Therapeutics BV
 Glycostem Therapeutics BV BiotechnologyHealth Technology Glycostem Therapeutics BV operates as a life science company which develops cellular immunotherapy and production technology platforms. It develops cellular immunotherapeutic for the treatment of leukemia, lymphomas, and other forms of cancer. The firm provides Prototype NK-cell and NK-cell progenitor cell products for clinical evaluations and intervention studies; and GBGM, a cell survival and minimal cellular delineation in expansion and differentiation experiments. The company was founded by Dirk Groenewegen and Jan van der Hoeven in 2007 and is headquartered in Oss, the Netherlands. | Directeur/Membre du Conseil | - |
Anciens postes connus de Wim Jongen
| Sociétés | Poste | Fin |
|---|---|---|
| Support Fund (Management) | Private Equity Investor | 31/12/2017 |
Glycostem Therapeutics BV
Glycostem Therapeutics BV BiotechnologyHealth Technology Glycostem Therapeutics BV operates as a life science company which develops cellular immunotherapy and production technology platforms. It develops cellular immunotherapeutic for the treatment of leukemia, lymphomas, and other forms of cancer. The firm provides Prototype NK-cell and NK-cell progenitor cell products for clinical evaluations and intervention studies; and GBGM, a cell survival and minimal cellular delineation in expansion and differentiation experiments. The company was founded by Dirk Groenewegen and Jan van der Hoeven in 2007 and is headquartered in Oss, the Netherlands. | Directeur Général | - |
| Wageningen University | Corporate Officer/Principal | - |
Wageningen Business Generator BV
 Wageningen Business Generator BV Miscellaneous Commercial ServicesCommercial Services Part of Wageningen University, Wageningen Business Generator BV identifies promising opportunities and turns them into thriving businesses. The company is based in Wageningen, Netherlands. | President | - |
Pepscan Therapeutics BV
 Pepscan Therapeutics BV Pharmaceuticals: MajorHealth Technology Pepscan Therapeutics BV develops immunotherapeutic products in oncology. The company was founded in 2000 and is headquartered in Lelystad, the Netherlands. | Président | - |
Formation de Wim Jongen
| Wageningen University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Streaming Valley BV
 Streaming Valley BV Miscellaneous Commercial ServicesCommercial Services Streaming Valley BV provides learning systems for educational purposes. It manufactures presentations 2Go, a comprehensive video platform for recording multi source video and capturing of live events, 360 degree video, management of content, metadata and multi platform streaming. The company was founded by Michaël Hegeman, Hendrik Klompmaker and Oscar Vonder in 2007 and is headquartered in Ede, the Netherlands. | Commercial Services |
Pepscan Therapeutics BV
Pepscan Therapeutics BV Pharmaceuticals: MajorHealth Technology Pepscan Therapeutics BV develops immunotherapeutic products in oncology. The company was founded in 2000 and is headquartered in Lelystad, the Netherlands. | Health Technology |
Wageningen Business Generator BV
Wageningen Business Generator BV Miscellaneous Commercial ServicesCommercial Services Part of Wageningen University, Wageningen Business Generator BV identifies promising opportunities and turns them into thriving businesses. The company is based in Wageningen, Netherlands. | Commercial Services |
| Support Fund (Management) | Finance |
Westertoren Innovation Ventures BV
Westertoren Innovation Ventures BV Investment ManagersFinance Westertoren Innovation Ventures BV (Westertoren Innovation Ventures) is a private equity and venture capital subsidiary of Biox Biosciences BV headquartered in 's-Hertogenbosch, Netherlands. The firm was founded in 2009. | Finance |
Glycostem Therapeutics BV
Glycostem Therapeutics BV BiotechnologyHealth Technology Glycostem Therapeutics BV operates as a life science company which develops cellular immunotherapy and production technology platforms. It develops cellular immunotherapeutic for the treatment of leukemia, lymphomas, and other forms of cancer. The firm provides Prototype NK-cell and NK-cell progenitor cell products for clinical evaluations and intervention studies; and GBGM, a cell survival and minimal cellular delineation in expansion and differentiation experiments. The company was founded by Dirk Groenewegen and Jan van der Hoeven in 2007 and is headquartered in Oss, the Netherlands. | Health Technology |
Netherlands Translational Research Center BV
Netherlands Translational Research Center BV Medical/Nursing ServicesHealth Services Netherlands Translational Research Center BV develops small molecule drug leads and preclinical candidates for cancer, autoimmune and Parkinson diseases. Its product NFK GreenScreen plays an important role in immune modulation and neurodegenerative disease. The firm also offers Oncolines, OncolinesProfiler, SynergyFinder, ResidenceTimer and EntropySelect services. The company was founded by Guido J. R. Zaman and Rogier C. Buijsman in June 2011 and is headquartered in Oss, the Netherlands. | Health Services |
Isobionics BV
Isobionics BV Chemicals: Major DiversifiedProcess Industries Isobionics BV operates as a holding company, which produces flavor and fragrance ingredients. The firm manufactures and supplies natural chemical substances such as Valencene, Nootkatone, and Beta-Elemene. The company was founded by Toine Janssen in 2008 and is headquartered in Geleen, the Netherlands. | Process Industries |
